These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 29761861)

  • 1. Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Sharma A; Al-Khatib SM; Ezekowitz JA; Cooper LB; Fordyce CB; Michael Felker G; Bardy GH; Poole JE; Thomas Bigger J; Buxton AE; Moss AJ; Friedman DJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Peterson ED; Inoue LYT; Sanders GD
    Eur J Heart Fail; 2018 Jun; 20(6):1031-1038. PubMed ID: 29761861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure.
    Fudim M; Ali-Ahmed F; Parzynski CS; Ambrosy AP; Friedman DJ; Pokorney SD; Curtis JP; Fonarow GC; Masoudi FA; Hernandez AF; Al-Khatib SM
    JAMA Cardiol; 2020 Jun; 5(6):643-651. PubMed ID: 32211811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.
    Rørth R; Dewan P; Kristensen SL; Jhund PS; Petrie MC; Køber L; McMurray JJV
    Clin Res Cardiol; 2019 Aug; 108(8):868-877. PubMed ID: 30689020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
    Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
    J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction.
    Chan LL; Lim CP; Aung ST; Quetua P; Ho KL; Chong D; Teo WS; Sim D; Ching CK
    Singapore Med J; 2016 Apr; 57(4):182-7. PubMed ID: 27075476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantable Cardioverter-Defibrillator Placement for Primary Prevention in 2,346 Patients: Predictors of One-Year Survival.
    Merchant FM; Desai Y; Addish MA; Kelly K; Casey M; Goyal A; Leon AR; El-Chami MF
    Tex Heart Inst J; 2018 Aug; 45(4):221-225. PubMed ID: 30374229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.
    Steinberg BA; Al-Khatib SM; Edwards R; Han J; Bardy GH; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Hallstrom A; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LY; Sanders GD
    JACC Heart Fail; 2014 Dec; 2(6):623-9. PubMed ID: 25306452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry.
    Kaiser DW; Tsai V; Heidenreich PA; Goldstein MK; Wang Y; Curtis J; Turakhia MP;
    Heart Rhythm; 2015 Oct; 12(10):2086-93. PubMed ID: 25982720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD
    Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
    Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.
    Karacan MN; Doi SN; Yafasova A; Thune JJ; Nielsen JC; Haarbo J; Bruun NE; Gustafsson F; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Pehrson S; Køber L; Butt JH
    Eur J Heart Fail; 2024 Jun; 26(6):1423-1431. PubMed ID: 38733253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.
    Adabag S; Patton KK; Buxton AE; Rector TS; Ensrud KE; Vakil K; Levy WC; Poole JE
    JAMA Cardiol; 2017 Jul; 2(7):767-774. PubMed ID: 28724134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure.
    Chia YMF; Teng TK; Tan ESJ; Tay WT; Richards AM; Chin CWL; Shimizu W; Park SW; Hung CL; Ling LH; Ngarmukos T; Omar R; Siswanto BB; Narasimhan C; Reyes EB; Yu CM; Anand I; MacDonald MR; Yap J; Zhang S; Finkelstein EA; Lam CSP
    Circ Cardiovasc Qual Outcomes; 2017 Nov; 10(11):. PubMed ID: 29150533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy.
    Briongos-Figuero S; Estévez A; Pérez ML; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Muñoz-Aguilera R
    ESC Heart Fail; 2020 Feb; 7(1):279-283. PubMed ID: 31823514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.
    Rørth R; Thune JJ; Nielsen JC; Haarbo J; Videbæk L; Korup E; Signorovitch J; Bruun NE; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Køber L; Kristensen SL
    Europace; 2019 Aug; 21(8):1203-1210. PubMed ID: 31323662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.